Dov Elefant
Net Worth

Last updated:

What is Dov Elefant net worth?

The estimated net worth of Mr. Dov Elefant is at least $2,310,316 as of 28 Dec 2020. He owns shares worth $55,366 as insider and has received compensation worth at least $2,254,950 in Cellectar Biosciences, Inc..

What is the salary of Dov Elefant?

Mr. Dov Elefant salary is $450,990 per year as Vice President & Chief Financial Officer in Cellectar Biosciences, Inc..

How old is Dov Elefant?

Mr. Dov Elefant is 58 years old, born in 1967.

What stocks does Dov Elefant currently own?

As insider, Mr. Dov Elefant owns shares in one company:

Company Title Shares Price per share Total value
Cellectar Biosciences, Inc. (CLRB) Vice President & Chief Financial Officer 11,755 $4.71 $55,366

What does Cellectar Biosciences, Inc. do?

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Dov Elefant insider trading

Cellectar Biosciences, Inc.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock 7,407 $1.35 $9,999
Purchase
Series H Warrants 2,174 $1.21 $2,626
Purchase
Common Stock 4,348 $1.15 $4,978

Cellectar Biosciences key executives

Cellectar Biosciences, Inc. executives and other stock owners filed with the SEC: